Secondary endpoints can be validly analysed, even if the primary endpoint does not provide clear statistical significance
Secondary outcomes are extremely important in early phase trials when the full benefits are still being discovered.
https://pubmed.ncbi.nlm.nih.gov/9408718/
Media, page-290
-
- There are more pages in this discussion • 454 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $537.4M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.5¢ | $459.4K | 1.254M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 63364 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 133642 | 8 |
View Market Depth
| Last trade - 16.10pm 27/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |